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as measured by 32P-postlabelling analysis, were signifi-
cantly higher in liver and kidney of Trp53(−/−) mice than 
of Trp53(+/+) mice. Complementarily, significantly higher 
amounts of BaP metabolites were also formed ex vivo in 
hepatic microsomes from BaP-pretreated Trp53(−/−) 
mice. Bypass of the need for metabolic activation by treat-
ing mice with BaP-7,8-dihydrodiol-9,10-epoxide resulted 
in similar adduct levels in liver and kidney in all mouse 
lines, confirming that the influence of p53 is on the bio-
transformation of the parent compound. Higher BaP-DNA 
adduct levels in the livers of Trp53(−/−) mice correlated 
with higher CYP1A protein levels and increased CYP1A 
enzyme activity in these animals. Our study demonstrates 
a role for p53 in the metabolism of BaP in vivo, confirm-
ing previous in vitro results on a novel role for p53 in 
CYP1A1-mediated BaP metabolism. However, our results 
also suggest that the mechanisms involved in the altered 
expression and activity of the CYP1A1 enzyme by p53 in 
vitro and in vivo are different.
Keywords Benzo[a]pyrene · Tumour suppressor 
p53 · Mouse models · Cytochrome P450 · Carcinogen 
metabolism · DNA adducts
Introduction
The TP53 tumour suppressor gene, which encodes the pro-
tein p53, is often described as the guardian of the genome 
and is the most commonly mutated gene in human tumours 
(Olivier et al. 2010). As gatekeeper, p53 regulates cell 
growth by inhibiting proliferation or promoting apopto-
sis (Taneja et al. 2011). As caretaker, it controls cellular 
processes to maintain genomic integrity, including repair 
to remove DNA damage (Taneja et al. 2011). Disruption 
Abstract The tumour suppressor p53 is one of the most 
important cancer genes. Previous findings have shown that 
p53 expression can influence DNA adduct formation of the 
environmental carcinogen benzo[a]pyrene (BaP) in human 
cells, indicating a role for p53 in the cytochrome P450 
(CYP) 1A1-mediated biotransformation of BaP in vitro. 
We investigated the potential role of p53 in xenobiotic 
metabolism in vivo by treating Trp53(+/+), Trp53(+/–) 
and Trp53(−/−) mice with BaP. BaP-DNA adduct levels, 
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of the normal p53 response by TP53 mutation leads to 
increased risks of tumour development. TP53 is mutated 
in over 50 % of sporadic tumours, and various environ-
mental carcinogens have been found to be associated with 
characteristic mutational signatures in TP53 (Olivier et al. 
2010). In addition to somatic mutations in the TP53 gene, 
germline mutations have been found to cause predisposi-
tion to cancer, and TP53 polymorphisms have been shown 
to increase cancer susceptibility (Whibley et al. 2009). 
Besides its role in DNA damage response, p53 has also 
been found to regulate metabolic pathways, thereby linking 
p53 not only to cancer, but also to other diseases such as 
diabetes and obesity (Maddocks and Vousden 2011).
Previously, we used a panel of isogenic human colorectal 
carcinoma HCT116 cell lines that differed only with respect 
to their endogenous TP53 status in order to investigate the 
metabolism and DNA damage induced by the environmen-
tal carcinogens benzo[a]pyrene (BaP) and 3-nitrobenzan-
throne (3-NBA) (Hockley et al. 2008; Wohak et al. 2014). 
We found that HCT116 TP53(−/−) and TP53(+/–) cells 
formed significantly lower BaP-DNA adduct levels than 
TP53(+/+) cells. In contrast, no difference in adduct for-
mation was observed in HCT116 cells exposed to BaP-7,8-
diol-9,10-epoxide (BPDE), the activated metabolite of BaP, 
indicating that p53 expression is linked to the cytochrome 
P450 (CYP)-mediated metabolic activation of BaP (com-
pare Supporting Figure 1a). There were also significantly 
lower levels of BaP metabolites detected in the culture 
media of HCT116 TP53(−/−) and TP53(+/–) cells relative 
to TP53(+/+) cells, which was accompanied by a greater 
induction of CYP1A1 protein and CYP1A1 mRNA in 
TP53(+/+) cells than in the other cell lines (Wohak et al. 
2014). We found that BaP-induced CYP1A1 expression 
was regulated through a p53 response element (p53RE) 
in the regulatory region of CYP1A1, thereby providing a 
novel pathway for the induction of CYP1A1 by polycyclic 
aromatic hydrocarbons (PAHs) such as BaP (Wohak et al. 
2014). Interestingly, DNA adduct formation by 3-NBA was 
not different in HCT116 TP53(+/+) and TP53(−/−) cells 
(Hockley et al. 2008), suggesting that NAD(P)H:quinone 
oxidoreductase (NQO1), which is the principal enzyme 
activating 3-NBA (compare Supporting Figure 1b) (Arlt 
et al. 2005; Stiborova et al. 2010), is not regulated by p53.
Transgenic and knockout mouse models have been used 
to study tumour suppressor function through phenotypic 
analysis of the whole organism and by examining a variety 
of primary cell types (Taneja et al. 2011). The opportunity 
to study multiple tissues is particularly useful for Trp53 
because p53 function is highly cell type specific (Done-
hower 2014; Kenzelmann Broz and Attardi 2010; Kucab 
et al. 2010; Lozano 2010). Much of the work carried out 
on the role of CYP enzymes in xenobiotic metabolism has 
been done in vitro (Nebert 2006; Nebert and Dalton 2006). 
However, extrapolation from in vitro data to in vivo phar-
macokinetics requires additional factors to be considered 
such as route of administration, absorption, renal clearance 
and tissue-specific CYP expression (Nebert 2006; Nebert 
et al. 2013). For example, previous studies have revealed an 
apparent paradox, whereby hepatic CYP enzymes appear to 
be more important for detoxification of BaP in vivo, despite 
being involved in its metabolic activation in vitro (Arlt 
et al. 2008, 2012; Nebert et al. 2013).
To evaluate the impact of the cellular Trp53 status on the 
metabolic activation of BaP and 3-NBA, we have compared 
metabolism and DNA adduct formation of BaP and 3-NBA 
in Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice. DNA 
adduct formation in vivo and in vitro was investigated 
by 32P-postlabelling analysis. Tissue-specific expression 
and activity of xenobiotic-metabolising enzymes (XMEs) 
involved in BaP and 3-NBA metabolism were compared 
with DNA adduct formation in the same tissue. Nucleotide 
excision repair (NER) capacity was assessed phenotypi-
cally in selected tissues using a modified comet assay. Uri-
nary BaP metabolites and the Cyp-mediated formation of 
BaP metabolites ex vivo in hepatic microsomes were meas-
ured by high-performance liquid chromatography (HPLC).
Materials and methods
Carcinogens
Benzo[a]pyrene (BaP; CAS number 50-32-8; purity 
≥96 %) was obtained from Sigma-Aldrich. 3-Nitrobenzan-
throne (3-NBA; CAS number 17117-34-9) was prepared as 
previously reported (Arlt et al. 2002). (±)-Anti-benzo[a]
pyrene-trans-7,8-dihydrodiol-9,10-epoxide (BPDE) was 
synthesised at the Biochemical Institute for Environmen-
tal Carcinogens, Prof. Dr. Gernot Grimmer-Foundation, 
Germany.
Carcinogen treatment of Trp53(+/+), Trp53(+/−) 
and Trp53(−/−) mice
Trp53(+/+), Trp53(+/–) and Trp53(−/−) male C57BL/6 
mice were generated as reported (Jacks et al. 1994). 
Trp53(+/−) and Trp53(−/−) mice carry a mutation which 
removes approximately 40 % of the coding capacity of 
Trp53 and completely eliminates synthesis of p53 protein. 
More information about the strains can be found at (http://
jaxmice.jax.org/strain/002101.html). All animal experi-
ments were conducted in accordance with the law at the 
Leiden University Medical Center, Leiden, the Nether-
lands, after approval by the institutional ethics committee. 
Animals were kept under controlled specific pathogen-
free conditions (23 °C, 40–50 % humidity) under a 12-h 
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light–dark cycle. Food and water were available ad libitum. 
Genotyping of the animals was performed as described 
(Jacks et al. 1994) (see Supporting Figure 2). Groups of 
male Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice 
(3 months old; 25–30 g; n = 4/group) were treated with 
a single dose of 125 mg/kg body weight (bw) of BaP by 
intraperitoneal (i.p.) injection according to treatment pro-
tocols used previously to study BaP metabolism (Arlt et al. 
2008, 2012). We chose i.p. injection as the administration 
route to achieve a high induction of hepatic CYP-mediated 
BaP metabolism. Similarly, groups (n = 4) of Trp53(+/+), 
Trp53(+/–) and Trp53(−/−) mice were injected i.p. with 
a single dose of 2 mg/kg bw of 3-NBA according to a pre-
vious study investigating 3-NBA metabolism (Arlt et al. 
2005). Based on dose-finding experiments in Trp53(+/+) 
mice using single i.p. injections of 1.25, 6.25 or 12.5 mg/kg 
bw of BPDE, groups (n = 4) of Trp53(+/+), Trp53(+/–) 
and Trp53(−/−) mice were treated i.p. with 1.25 mg/kg bw 
of BPDE. Control mice (n = 4) received solvent (corn oil) 
only. Animals were killed 24 h after treatment, and their 
liver, lung, kidney, colon, small intestine, bladder, glandu-
lar stomach, forestomach and spleen were removed, snap-
frozen in liquid nitrogen and stored at −80 °C until further 
analysis. Urine was collected for the preceding 24 h.
Detection of DNA adducts by 32P‑postlabelling
DNA was isolated from tissues by a standard phenol–chlo-
roform extraction method. DNA adduct analysis was per-
formed by thin-layer chromatography 32P-postlabelling 
analysis (Phillips and Arlt 2007, 2014). For DNA from 
BaP- and BPDE-treated animals, the nuclease P1 digestion 
enrichment method was used (Arlt et al. 2008), while for 
DNA from 3-NBA-treated animals, the butanol extraction 
method was employed (Arlt et al. 2002). DNA samples 
(4 μg) were digested with micrococcal nuclease (288 mU; 
Sigma) and calf spleen phosphodiesterase (1.2 mU; MP 
Biomedical) and then enriched and labelled as reported.
Measurement of nucleotide excision repair (NER) 
capacity
The ability of NER-related enzymes present in isolated tis-
sue extracts to detect and incise substrate DNA containing 
BPDE-DNA adducts was measured using a modified comet 
assay (Langie et al. 2006). Tissue protein extracts were 
prepared as described previously (Güngör et al. 2010), 
and protein concentrations were optimised for analysis of 
liver and kidney samples (0.2 mg/mL). The ex vivo repair 
incubation and electrophoresis were performed according 
to the published protocol (Langie et al. 2006). Dried slides 
stained with ethidium bromide (10 µg/mL) were viewed 
with a Zeiss Axioskop fluorescence microscope. Comets 
were scored using the Comet III system (Perceptive Instru-
ments, UK). Fifty nucleoids were assessed per slide, and 
each sample was analysed in duplicate. All samples were 
measured blindly. Tail intensity (% tail DNA), defined 
as the percentage of DNA migrated from the head of the 
comet to the tail, was used to calculate repair capacity of 
the tissue extracts as reported previously (Langie et al. 
2006).
Preparation of microsomal and cytosolic samples
Microsomal and cytosolic fractions were isolated from 
the livers and lungs of Trp53(+/+), Trp53(+/–) and 
Trp53(−/−) mice. Tissue frozen in liquid nitrogen was 
ground up in a Teflon container with a steel ball in a dis-
membrator to a frozen powder. This was transferred into 
a Potter-Elvehjem homogenizer and the Teflon receptacle 
rinsed with 1/15 M sodium phosphate buffer with 0.5 % 
potassium chloride pH 7.4. The powder was homogenised 
and transferred to a centrifuge tube and the potter rinsed 
with phosphate buffer. The homogenates were spun for 
30 min at 18,000×g. Supernatant were transferred to an 
ultracentrifuge tube and spun at 100,000×g for 60 min 
at 4 °C. The resulting supernatants formed the cytosols, 
which was levered off the sediment gently, while the sedi-
ments (microsomes) were taken up in phosphate buffer. 
Protein concentration in the fractions was measured using 
bicinchoninic acid protein assay (Wiechelman et al. 1988) 
with bovine serum albumin and stored in small aliquots at 
−80 °C until analysis.
Microsomal BaP‑DNA adduct formation
Incubation mixtures in a final volume of 750 µL consisted 
of 50 mM potassium phosphate buffer (pH 7.4), 1 mM 
NADPH, 0.5 mg of microsomal protein, 0.5 mg calf thy-
mus DNA and 0.1 mM BaP [dissolved in 7.5 µL dimethyl-
sulfoxide (DMSO)]. The reaction was initiated by adding 
NADPH. Microsomal incubations were carried out at 37 °C 
for 90 min. Microsomal-mediated BaP-DNA adduct forma-
tion was linear up to 120 min as reported previously (Arlt 
et al. 2008). Control incubations were carried out (i) with-
out microsomes, (ii) without NADPH, (iii) without DNA 
and (iv) without BaP. After incubation, DNA was isolated 
by a standard phenol/chloroform extraction method.
Microsomal BaP metabolite formation
In a final volume of 500 µL, the incubation mixture con-
tained 100 mM potassium phosphate buffer (pH 7.4), 
NADPH-generating system (1 mM NADP+, 10 mM d-glu-
cose-6-phosphate, 1 μ/mL d-glucose-6-phosphate dehy-
drogenase), 0.5 mg microsomal protein and 50 µM BaP 
842 Arch Toxicol (2016) 90:839–851
1 3
(dissolved in 5 µL DMSO). The reaction was initiated by 
adding 50 µL of the NADPH-generating system. Microso-
mal incubations were carried out at 37 °C for 20 min. Con-
trol incubations were carried out (1) without microsomes, 
(2) without NADPH-generating system and (3) without 
BaP. After incubation, 5 µL of 1 mM phenacetin in metha-
nol was added as internal standard. The BaP mixtures were 
extracted with ethyl acetate (2 × 1 mL), the solvent was 
evaporated to dryness, and the residue was dissolved in 
25 µL methanol for HPLC analysis.
HPLC analysis of BaP metabolites
HPLC analysis was performed on a Nucleosil® C18 
reversed phase column (250 × 4 mm, 5 µm; Macherey 
Nagel, Germany), using a Dionex system consisting of a 
pump P580, a UV/VIS Detector UVD 170S/340S, an ASI-
100 Automated Sample Injector, a termobox COLUMN 
OVEN LCO 101 and an In-Line Mobile Phase Degasser 
Degasys DG-1210 Dionex controlled with ChromeleonTM 
6.11 build 490 software. HPLC conditions were as follows: 
50 % acetonitrile in HPLC water (v/v), with a linear gradi-
ent to 85 % acetonitrile in 35 min, then an isocratic elu-
tion with 85 % acetonitrile for 5 min, a linear gradient from 
85 % acetonitrile to 50 % acetonitrile in 5 min, followed by 
an isocratic elution of 50 % acetonitrile for 5 min. Detec-
tion was by UV at 254 nm. BaP metabolite peaks were 
collected and analysed by NMR and/or mass spectrometry 
as described (Stiborova et al. 2014). The structures of BaP 
metabolites analysed are given in Supplementary Figure 8. 
The metabolite peak areas were calculated relative to the 
peak area of the internal standard.
BaP metabolites in urine
Urine samples (0.4–1.7 mL) collected from Trp53(+/+) 
and Trp53(−/−) mice treated with BaP were mixed with 
four volumes of methanol and centrifuged for 4 min at 
1000 rpm, and the supernatants were then evaporated to 
dryness. The residues were dissolved in 100 µL of metha-
nol and analysed by HPLC as described above. Urine sam-
ples for Trp53(+/–) mice were lost during analysis.
Expression of Cyp1a1 and Nqo1 by Western blotting
Microsomal and cytosolic proteins were separated using 
NuPage 4–12 % Bis–Tris sodium-dodecyl sulphate (SDS)-
polyacrylamide gels (Life Technologies) and Western-
blotted as previously reported (Hockley et al. 2006). 
Chicken polyclonal antibody raised against recombinant 
rat CYP1A1 protein (Arlt et al. 2008) has been shown to 
recognise murine Cyp1a1. In microsomal samples, Cyp1a1 
was probed with chicken anti-rat CYP1A1 at 1:5000, and 
peroxidase-conjugated goat anti-chicken (ab6877, Abcam, 
1:10,000) was used as secondary antibody. Rat recombinant 
CYP1A1 and CYP1A2 (in Supersomes™, Gentest Corp.) 
were used as positive controls to identify protein bands 
in microsomal samples. In cytosolic samples, an affinity-
purified rabbit antibody was used to detect Nqo1 (N5288, 
rabbit pAb, 1:10,000; Sigma) and peroxidase-conjugated 
goat anti-rabbit antibody (CST7076, Cell Signalling Tech-
nology, 1:10,000) was used as secondary antibody. Human 
recombinant NQO1 (Sigma) was used as positive control 
to identify the nqo1 band in cytosols. Gapdh was detected 
with mouse mAb #MAB374 (1:10,000; Millipore) and 
β-actin with mouse mAb ab6276 (1:10,000; Abcam) using 
peroxidase-conjugated goat anti-mouse as secondary anti-
body #170-5047 (1:5000; Bio-Rad). All proteins were visu-
alised using the enhanced chemiluminescent SuperSignal 
West Pico detection reagent according to the manufactur-
er’s instruction (#34080; Thermo Scientific).
Measurement of Cyp1a1 enzyme activity
Microsomal samples were characterised for Cyp1a activity 
using 7-ethoxyresorufin O-deethylation (EROD) activity 
(Mizerovska et al. 2011). Enzyme activity was determined 
by following the conversion of 7-ethoxyresorufin into 
resorufin using fluorescent measurement on a Synergy HT 
Plate Reader (Bio-TEK) using an excitation wavelength of 
530 nm and an emission wavelength of 580 nm.
Measurement of Nqo1 enzyme activity
Nqo1 enzyme activity in cytosolic samples was measured 
with menadione (2-methyl-1,4-naphthoquinone) as sub-
strate as described previously (Mizerovska et al. 2011). 
Enzyme activity was determined by following the conver-
sion of cytochrome c at 550 nm on a Synergy HT Plate 
Reader (Bio-TEK).
Expression of p53 by Western blotting
For the preparation of whole hepatic protein, extracts of 
liver tissues (30 mg) of Trp53(+/+) mice were homog-
enised in 300 µL of Tissue Protein Extraction Reagent 
(T-PER™, Life Technologies) buffer supplemented with 
1 % protease inhibitor (Halt™, Life Technologies). Sam-
ples were sonicated and centrifuged for 20 min at 13,000g 
(4 °C), and the supernatant was saved. The protein con-
centration was measured as described above. For Western 
blotting, 25 µg of protein was separated by SDS–poly-
acrylamide electrophoresis as described above. The fol-
lowing antibodies were used: anti-p53 (rabbit pAb, NCL-
p53-CM5p, 1:5000; Leica Biosystems) and anti-Gadph 
(mouse mAb #MAB374, 1:10,000; Millipore). Membranes 
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were washed and incubated with peroxidase-conjugated 
goat anti-rabbit or goat anti-mouse as secondary antibodies 
(#170-5046 and #170-5047, 1:5000; Bio-Rad).
Results
DNA adduct formation in vivo
In the majority of tissues, the BaP-DNA adduct pattern con-
sisted of a single adduct spot (spot 1), previously identified 
as 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydro-BaP (dG-N2-BPDE) (Supporting Figure 3a). For 
lung, colon and small intestine additional adduct spots were 
detected. In all three tissues, a minor adduct (spot 2) was 
detected that was previously suggested to be derived from 
reaction of 9-hydroxy-BaP-4,5-epoxide with guanine (Sti-
borova et al. 2014), while for colon and small intestine, an 
additional major adduct (spot 3) was found that has not yet 
been structurally identified. The same adduct profiles were 
observed in all three mouse lines. A scheme showing the 
formation of adducts 1 and 2 is given in Supporting Fig-
ure 6. No DNA adducts were detected in control animals 
(data not shown).
BaP-DNA adduct levels ranged from 25 to 100 adducts 
per 108 nucleotides (Fig. 1a). Adduct levels were signifi-
cantly higher (~ twofold) in livers of Trp53(−/−) compared 
to Trp53(+/+) mice (106 ± 25 versus 48 ± 27 adducts per 
108 nucleotides; p < 0.05), while adduct formation in kid-
ney was significantly higher (~ twofold) in both Trp53(+/–) 
and Trp53(−/−) relative to Trp53(+/+) mice (73 ± 31 and 
70 ± 20 versus 27 ± 6 adducts per 108 nucleotides, respec-
tively; p < 0.05). A similar trend was observed in lung, fore 
stomach and spleen, although the difference in adduct lev-
els did not reach statistical significance. In contrast, adduct 
levels in liver, lung and kidney did not significantly change 
after treatment with BPDE in all mouse lines (Fig. 1b). In 
these tissues, the adduct pattern consisted of adduct spot 1 
only (see Supporting Figure 3b). As BPDE does not require 
CYP-mediated metabolic activation to bind to DNA, these 
findings suggest that the differences in DNA adduct forma-
tion observed in liver and kidney with the parent compound 
BaP are the consequence of the different capacities of the 
Trp53 mouse lines to metabolically activate BaP.
The adduct pattern induced by 3-NBA consisted of 
up to four adduct spots (spots 1–4; Supporting Figure 4). 
These were characterised previously as 2-(2′-deoxyaden-
osin-N6-yl)-3-aminobenzanthrone (dA-N6-3-ABA; spot 
1), 2-(2′-deoxyguanosin-N2-yl)-3-aminobenzanthrone 
(dG-N2-3-ABA; spot 3) and N-(2′-deoxyguanosin-8-yl)-
3-aminobenzanthrone (dG-C8-N-3-ABA; spot 4), while 
spot 2 is an as-yet-uncharacterised deoxyadenosine adduct 
(Arlt et al. 2001, 2006). Adduct levels ranged from 2 to 40 
adducts per 108 nucleotides, but there were no significant 
differences between mouse lines in DNA adduct formation 
in any of the tissues investigated (Fig. 2). These results sug-
gest that in contrast to BaP metabolism, Trp53 status has no 
impact on 3-NBA metabolism in vivo, which is in accord 
with experiments on human cells in vitro (Hockley et al. 
2008; Simoes et al. 2008).
DNA repair capacity in liver and kidney
As p53-dependent pathways affecting global NER have 
been identified (Ford 2005; Sengupta and Harris 2005), 
we assessed whether mouse Trp53 status influences 
NER activity. Tissue extracts from liver and kidney were 
examined for their ability to repair BPDE-induced DNA 
adducts using a modified comet assay (Langie et al. 2006). 
We found that in the liver, the repair capacity was ~50 % 
higher in Trp53(−/−) than in Trp53(+/+) mice, while no 
difference in the repair capacity between mouse lines was 
observed in kidney (Supporting Figure 12).
DNA adduct formation of BaP ex vivo
We investigated the ability of hepatic microsomes isolated 
from both control and BaP-treated animals to catalyse 
BaP-DNA adduct formation ex vivo (Fig. 3; Supporting 
Figure 5). While Trp53 status had no influence on DNA 
adduct formation by BaP with hepatic microsomes iso-
lated from untreated animals (Supporting Figure 5), BaP-
induced adduct levels were significantly higher with micro-
somal samples from Trp53(+/–) and Trp53(−/−) relative 
to Trp53(+/+) mice pretreated with BaP (Fig. 3). The 
adduct pattern induced by BaP ex vivo consisted of adduct 
spots 1 and 2 (see inserts Fig. 3 and Supporting Figure 5). 
Interestingly, adduct levels of adduct 2 were higher than 
adduct 1, the dG-N2-BPDE adduct, and, in addition, adduct 
2 was significantly higher in experiments with Trp53(+/–) 
and Trp53(−/−) microsomes than with Trp53(+/+) 
microsomes.
BaP metabolite profile ex vivo
As our data suggested that Trp53 status affects the 
NADPH-dependent metabolic activation of BaP in hepatic 
microsomes, metabolite profiles were determined by HPLC 
analysis. First, we investigated whether the hepatic micro-
somes isolated from BaP-treated mice contained residual 
BaP and/or its metabolites. No amounts of BaP and BaP 
metabolites were detectable in these microsomal fractions 
(Supporting Figure 7c–e). To determine the BaP metabo-
lite profile, hepatic microsomes isolated from Trp53(+/+), 
Trp53(+/–) and Trp53(−/−) were incubated with BaP and 
subsequently analysed by HPLC analysis. A representative 
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HPLC chromatogram of BaP metabolites formed in ex vivo 
incubations containing microsomes, NADPH and BaP is 
shown in Supporting Figure 7a.
Hydroxylated BaP metabolites, BaP-dihydrodiols and 
BaP-diones were identified (see Supporting Figure 8). Pre-
vious studies have shown that many of these BaP metabo-
lites are formed by CYP1A1 in combination with micro-
somal epoxide hydrolase (Bauer et al. 1995; Kim et al. 
1998; Luch and Baird 2005). No BaP metabolites were 
detected in control incubations without microsomes, with-
out NADPH-generating system or without BaP (Support-
ing Figure 7b, c). With hepatic microsomes isolated from 
untreated mice, Trp53 status had no influence on the BaP 
metabolite profile and the amounts of BaP metabolites 
formed (Supporting Figure 9). However, pretreating mice 
with BaP led to a significant increase in BaP metabolite 
formation ex vivo (Fig. 4). Moreover, amounts of BaP-
7,8-dihydrodiol, BaP-1,6-dione, BaP-3,6-dione, BaP-9-ol 
and BaP-3-ol were significantly higher in microsomes of 
pretreated Trp53(+/–) and Trp53(−/−) mice compared 
with pretreated Trp53(+/+) mice. These findings corre-
lated with ex vivo BaP-DNA adduct formation using the 
same hepatic microsomes (compare Fig. 3).
Urine analysis of Trp53(+/+) and Trp53(−/−) mice 
treated with BaP
A representative HPLC chromatogram of urinary BaP 
metabolites is shown in Supporting Figure 13a. The 
amounts of BaP-4,5-dihydrodiol, BaP-7,8-dihydrodiol, 
BaP-3,6-dione and BaP-3-ol were significantly lower in 
urine of Trp53(−/−) compared to Trp53(+/+) mice (Sup-
porting Figure 13b), although most of the differences were 
small (~15–20 % reduction). BaP metabolites can be conju-
gated to glucuronides and sulphates (Luch and Baird 2005), 
which are excreted in the urine and faeces, but only uncon-
jugated BaP metabolites (see Supporting Figure 8) were 
determined in the present work.
Fig. 1  DNA adduct levels 
measured by 32P-postlabel-
ling in various organs of 
Trp53(+/+), Trp53(+/–) 
and Trp53(−/−) mice after 
exposure to BaP (a) or BPDE 
(b). Values are the mean ± SD 
(n = 4). Statistical analysis was 
performed by one-way ANOVA 
followed by Tukey post hoc 
test [*p < 0.05; different from 
Trp53(+/+) mice]
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Influence of Trp53 status on xenobiotic‑metabolising 
enzymes
We next studied the expression and activity of enzymes 
metabolising BaP. Metabolic activation of BaP is cata-
lysed mainly by CYP1A1, but also CYP1B1 (Supporting 
Figure 1a), which leads via BPDE to the formation of dG-
N2-BPDE, the major BaP-derived DNA adduct detected in 
vivo. For these investigations, we selected liver, as Trp53 
status impacted on hepatic BaP-DNA adduct formation 
(see Fig. 1a), and also lung, because it is the main target 
organ of 3-NBA genotoxicity (Arlt 2005).
Treatment of mice with BaP led to a large induc-
tion of Cyp1a1 protein levels in liver (Fig. 5a). However, 
induction was much greater in hepatic microsomes of 
BaP-treated Trp53(+/–) and Trp53(−/−) mice than of 
Trp53(+/+) mice, which correlates with the levels of BaP-
DNA adducts in the livers of these animals. In this con-
text, it may be noteworthy that no induction of p53 pro-
tein levels was observed after BaP treatment in the livers 
of Trp53(+/+) mice (Supporting Figure 10). The increase 
in Cyp1a1 protein levels was associated with a significant 
increase in EROD activity (up to ~ twofold; p < 0.05), 
a measure of CYP1A enzyme activity, in BaP-treated 
Trp53(+/–) and Trp53(−/−) compared with Trp53(+/+) 
mice (Fig. 6a). In contrast, Trp53 status had no effect on 
EROD activity in hepatic microsomes isolated from con-
trol (untreated) mice (see Supporting Figure 11a), which 
was in line with no changes being observed in ex vivo 
BaP-DNA adduct formation (compare Supporting Fig-
ure 5) and BaP metabolite formation ex vivo using the 
same microsomes (compare Supporting Figure 9). Cyp1a1 
protein levels were increased in pulmonary microsomes 
isolated from BaP-treated Trp53(−/−) compared to 
Trp53(+/+) (Fig. 5a), but no significant change in EROD 
activity was observed (Fig. 6b). Lung microsomes isolated 
from control (untreated) mice showed variability in EROD 
activity between preparations and/or experiments (com-
pare Supporting Figure 11b, d) which may also be linked 
to low basal activity in these microsomes. No changes for 
Cyp1a1 protein levels, which were close to background 
levels (Fig. 5a), or enzyme activity (Fig. 6c, d) were 
observed in hepatic and pulmonary microsomes isolated 
from mice treated with 3-NBA between Trp53 genotypes. 
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Fig. 2  DNA adduct levels measured by 32P-postlabelling in various 
organs of Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice after expo-
sure to 3-NBA. Values are the mean ± SD (n = 4). Statistical analysis 
was performed by one-way ANOVA followed by Tukey post hoc test; 
no significant differences were observed
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Fig. 3  BaP-DNA adducts, measured by 32P-postlabelling, formed 
ex vivo by hepatic microsomes isolated from BaP-pretreated 
Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice. Values are the 
mean ± range (n = 4); duplicate incubations and each sample were 
determined by two independent post-labelled analyses. Statistical 
analysis was performed by one-way ANOVA followed by Tukey post 
hoc test [**p < 0.01; different from hepatic microsomes isolated from 
Trp53(+/+) mice]. Insert autoradiographic profiles of DNA adducts 
formed in hepatic microsomes isolated from Trp53(+/+) mice; the 
origins, at the bottom left-hand corners, were cut off before exposure
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The principal enzyme that activates 3-NBA by nitrore-
duction is NQO1 (Supporting Figure 1b) (Arlt et al. 2005; 
Stiborova et al. 2010). The resulting N-hydroxy-3-amin-
obenzanthrone (N–OH-3-ABA) can spontaneously form 
reactive nitrenium ions capable of forming DNA adducts. 
Alternatively, N–OH-3-ABA can be further activated by 
N-acetyltransferases or sulfotransferases, leading to the 
formation of the same reactive nitrenium ions (Arlt 2005). 
It has been shown that in vivo cytosolic nitroreduction of 
3-NBA is more important than nitroreduction by micro-
somal NAD(P)H:cytochrome P450 oxidoreductase (Arlt 
et al. 2003, 2005). As we did not observe any differences 
in DNA adduct formation with 3-NBA, we measured the 
expression and activity of Nqo1 in hepatic and pulmo-
nary cytosols. In addition, as BaP-derivatives can also 
be metabolised by NQO1 (Luch and Baird 2005), we 
also determined expression and activity of Nqo1 in mice 
exposed to BaP.
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mice (c). Relative peak areas of BaP metabolites were measured by 
HPLC analysis at 254 nm. Values are the mean ± SD (n = 3). Sta-
tistical analysis was performed by one-way ANOVA followed by 
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All cytosolic samples contained Nqo1 (Fig. 5b). In both 
liver and lung, BaP treatment led to an induction of Nqo1 
(Fig. 5b) that was independent of the Trp53 genotype of the 
animals. These findings were in line with increased Nqo1 
enzyme activity in these animals after BaP treatment (com-
pare Supporting Figure 11e, f); however, Trp53 status had 
no effect on Nqo1 enzyme activity in either organ, with or 
without BaP pretreatment of the animals. In hepatic cyto-
sols, Nqo1 protein levels were unchanged in 3-NBA-treated 
mice (Fig. 5b). Nqo1 protein levels were increased in the 
lungs of 3-NBA-treated Trp53(+/+) mice, which is in con-
cordance with previous studies showing that 3-NBA expo-
sure can induce NQO1 (Stiborova et al. 2006, 2008), but not 
in 3-NBA-treated Trp53(+/–) and Trp53(−/−) mice. Expo-
sure to 3-NBA and Trp53 genotype had no impact on Nqo1 
enzyme activity in hepatic and pulmonary cytosols (Fig. 6g, 
h; Supporting Figure 11g, h); however, strong variability 
in Nqo1 activity was seen in lung cytosols isolated from 
3-NBA-treated Trp53(+/+) mice (Supporting Figure 11h). 
Collectively, these results suggest that p53 expression has 
no impact on Nqo1-mediated bioactivation of 3-NBA, 
which correlates with the lack of influence of Trp53 geno-
type on 3-NBA-DNA adduct formation in vivo (Fig. 2).
Discussion
We used Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice to 
investigate the effect of p53 on BaP metabolism and DNA 
adduct formation induced by BaP in vivo. The BaP dose 
used in this study, 125 mg/kg bw, has been shown to be 
carcinogenic and able to induce mutagenicity in multiple 
organs after repeated administration (Hakura et al. 1998). 
We found that BaP-induced DNA adduct formation in liver 
and kidney was significantly higher in Trp53(−/−) mice 
than in Trp53(+/+) mice after acute BaP treatment. Simi-
lar trends in DNA adduct formation were seen in other tis-
sues (e.g. lung), although the difference in adduct forma-
tion did not reach statistical significance. This is in contrast 
to another study examining the effect of pentachlorophenol 
on DNA adduct formation in Trp53(+/+) and Trp53(−/−) 
mice exposed to BaP (Ress et al. 2002). In that study, no 
influence of Trp53 status on BaP-DNA adduct formation 
was evident in the tissues investigated, namely liver and 
lung. The discrepancy between the two studies could be 
attributable to the different dosing regimens (i.e. a higher 
BaP dose was used in our study), but otherwise remains 
unexplained at present. CYP1A1 is considered to be one 
of the key enzymes responsible for the metabolic activa-
tion of BaP in organisms (Luch and Baird 2005). Our data 
showed that higher BaP-DNA adduct levels in the livers of 
Trp53(−/−) mice relative to Trp53(+/+) mice correlated 
with higher hepatic Cyp1a protein levels and increased 
Cyp1a enzyme activity in these animals.
The amounts of BaP metabolites and BaP-DNA 
adduct levels formed in incubations using hepatic micro-
somes isolated from BaP-pretreated Trp53(−/−) and 
Trp53(+/–) mice were higher than when using those from 
Fig. 6  EROD activity (a–d) in 
hepatic (a, c) and pulmonary 
microsomes (b, d) isolated from 
Trp53(+/+), Trp53(+/–) and 
Trp53(−/−) mice exposed to 
BaP or 3-NBA. Nqo1 enzyme 
activity (e–h) was determined in 
hepatic (e and g) and pulmonary 
cytosols (f and h) isolated from 
Trp53(+/+), Trp53(+/–) and 
Trp53(−/−) mice exposed to 
BaP or 3-NBA. Values are the 
mean ± SD (n = 4). Statistical 
analysis was performed by one-
way ANOVA followed by Tukey 
post hoc test [*p < 0.05; differ-
ent from Trp53(+/+) mice]
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BaP-pretreated Trp53(+/+) mice. This indicates again 
that Cyp activity was induced in Trp53(−/−) mice which 
correlated with higher BaP-DNA adduct formation in this 
mouse line. However, studying BaP-DNA adduct forma-
tion ex vivo, we found that adduct 2, but not formation of 
dG-N2-BPDE, was higher in experiments with Trp53(+/–) 
and Trp53(−/−) microsomes than with Trp53(+/+) 
microsomes, whereas dG-N2-BPDE levels were twice as 
high in livers of Trp53(−/−) mice relative to Trp53(+/+) 
mice in vivo. The presence of both adducts in the micro-
somal incubation ex vivo can be explained by different 
metabolic pathways, leading to the formation of the precur-
sors of each adduct (see Supporting Figure 6). The levels 
of adduct 2 correlated well with Cyp1a enzyme activity 
in ex vivo incubations with hepatic microsomes because 
they are solely dictated by the Cyp1a-mediated formation 
of 9-hydroxy-BaP-4,5-epoxide (Stiborova et al. 2014). In 
contrast, formation of dG-N2-BPDE strongly depends on 
the activity of microsomal epoxide hydrolase (mEH) which 
catalyses the hydration of BaP-7,8-epoxide to BaP-7,8-di-
hydrodiol which is the precursor of BPDE (see Supporting 
Figure 6). The formation of BaP-7,8-dihydrodiol in vivo 
should be more effective than ex vivo because, in addition 
to mEH present in hepatic microsomes used in the ex vivo 
incubations, other EH isoenzymes can catalyse the hydra-
tion reaction in vivo. Nevertheless, our ex vivo incubations 
demonstrate that Cyp-mediated BaP-DNA adduct forma-
tion is dependent on Trp53 status.
Studies investigating xenobiotic metabolism and/or 
carcinogen-DNA adduct formation in transgenic mice 
with altered Trp53 status are sparse and have mainly 
used Trp53(+/–) mice (Ariyoshi et al. 2001; Carmichael 
et al. 2001; Mori et al. 2001; Sanders et al. 2001). In one 
study, DNA adduct levels induced by diethylstilbestrol 
(DES) were ~twofold higher in Trp53(+/–) mice than in 
Trp53(+/+) mice (Carmichael et al. 2001). Small differ-
ences in the protein expression of several Cyp enzymes 
including Cyp1a1/2, Cyp1b1, Cyp2b9 and Cyp3a11 were 
observed, and it was concluded that these differences in the 
expression of XMEs between Trp53(+/–) and Trp53(+/+) 
mice could have contributed to the higher DES-induced 
DNA adduct levels seen in Trp53(+/–) mice. In this con-
text, it is noteworthy that we also found higher DNA 
adduct levels in Trp53(+/–) mice relative to Trp53(+/+) 
mice after BaP exposure. Another study found that hepatic 
Cyp1a protein induction was higher in female Trp53(+/–) 
mice than in Trp53(+/+) mice after treatment with another 
PAH, 3-methylcholanthrene (Ariyoshi et al. 2001). This 
finding is in line with our results, showing that Cyp1a pro-
tein levels and Cyp1a enzyme activity are increased in the 
livers of Trp53(+/–) animals after BaP exposure. Other 
studies found no difference in the Cyp-mediated metabo-
lism of N-butyl-N-(4-hydroxy-butyl)nitrosamine, benzene, 
ethoxyquin or methacrylonitrile between Trp53(+/+) and 
Trp53(+/–) mice (Mori et al. 2001; Sanders et al. 2001).
Haploinsufficiency in TP53 has been shown to promote 
tumour development (Berger and Pandolfi 2011) as reduc-
tion in p53 gene dosage can impact on a cell’s ability to 
respond to DNA damage (Berger et al. 2011). As such, 
survival of Trp53(+/–) mice shows an intermediate sur-
vival to that of Trp53(−/−) and Trp53(+/+) mice, and 
tumours that develop in Trp53(+/–) mice do not always 
display loss of the remaining wild-type allele (Berger et al. 
2011). Interestingly, in kidney, Trp53(+/–) mice behaved 
like Trp53(−/−), showing higher BaP-DNA adduct levels 
relative to Trp53(+/+) mice, while adduct formation in 
the livers of Trp53(+/–) and Trp53(+/+) mice was similar 
but lower compared to Trp53(−/−) mice. However, both 
hepatic Cyp1a protein levels and Cyp1a enzyme activity 
were higher in BaP-treated Trp53(+/–) and Trp53(−/−) 
mice than in Trp53(+/+) mice, suggesting that in 
Trp53(+/–) animals, other factors besides Cyp1a expres-
sion may influence BaP-DNA adduct formation in the liver.
NER is considered to be the main DNA repair path-
way for bulky DNA adducts (Kucab et al. 2015), and 
p53-dependent pathways affecting global genomic NER 
have been identified (Ford 2005; Sengupta and Harris 
2005). A modified comet assay measuring the tissue-spe-
cific NER capacity in untreated (control) animals showed 
no impact of Trp53 status in kidney but an significant 
increase in NER capacity in Trp53(−/−) mice relative to 
Trp53(+/+) mice in liver. Although it is possible that BaP 
treatment may impact on NER capacity, a recent in vivo 
study has shown no transcriptomic responses related to 
NER genes in mice exposed to BaP (van Kesteren et al. 
2013). Therefore, our results suggest that tissue-spe-
cific NER capacity did not contribute to the higher BaP-
DNA adduct levels observed in Trp53(−/−) mice than in 
Trp53(+/+) mice, in both liver and kidney. This conclu-
sion was strengthened by the fact that DNA adduct forma-
tion in livers and kidneys of Trp53(+/+), Trp53(+/–) and 
Trp53(−/−) mice exposed to the corresponding reactive 
metabolite of BaP, BPDE, resulted in similar adduct levels 
in all mouse lines. As treatment with BPDE bypasses the 
need for metabolic activation, these results again indicated 
that the level of p53 expression impacts on the metabolic 
activation of the parent compound, BaP, but not on DNA 
repair.
Previous studies conducted in a panel of isogenic human 
cells differing only with respect to their endogenous TP53 
status showed that complete loss of p53 function (i.e. 
TP53(−/−) cells) resulted in considerably lower BaP-DNA 
adduct levels compared to TP53(+/+) cells after BaP expo-
sure (Hockley et al. 2008; Wohak et al. 2014). CYP1A1 
protein expression was induced to a much greater extent in 
TP53(+/+) cells than in TP53(+/–) and TP53(−/−) cells. 
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There were also significantly lower levels of BaP metabo-
lites in the culture medium of TP53(+/–) and TP53(−/−) 
cells correlating with lower BaP-DNA adduct formation in 
these cell lines. It was also shown that exposure to BPDE 
resulted in similar adduct levels in all cell lines and that 
NER capacity did not contribute to the observed differences 
in BaP-DNA adduct formation as the repair capacity was 
the same in all cell lines (Wohak et al. 2014). Collectively, 
these results demonstrate the role of p53 in the CYP1A1-
mediated metabolism of BaP in human cells.
However, the impact of p53 function on BaP metabolism 
is different in vitro and in vivo. Whereas loss of p53 func-
tion results in a decrease in BaP-DNA adduct formation 
in vitro, loss of p53 function in vivo leads to an increase 
in BaP-DNA adduct formation. Other studies (Arlt et al. 
2008; Nebert et al. 2013) have revealed a paradox, whereby 
CYP enzymes (particularly CYP1A1) appear to be more 
important for detoxification of BaP in vivo, despite being 
involved in its metabolic activation in vitro, demonstrating 
that XMEs can have different effects on carcinogen metab-
olism in vitro and in vivo. Nevertheless, the mechanism 
involved in the altered expression and activity of Cyp1a 
enzymes by p53 function in mice is presently unclear. It 
may not always be possible to extrapolate from in vitro data 
to in vivo pharmacokinetics as additional factors need to 
be considered such as route of administration, absorption, 
renal clearance and tissue-specific CYP expression (Arlt 
et al. 2008). Additionally, it will be necessary to examine 
whether there are species-dependent differences between 
cultured human and mouse cells in the p53-dependent BaP 
metabolism in vitro.
Many studies have shown that BaP can induce CYP1A1 
through binding to the aryl hydrocarbon receptor (Ahr), a 
transcription factor that also regulates the expression of a 
number of phase I and phase II XME genes (Shimizu et al. 
2000; Wang et al. 2011). However, when BaP was admin-
istered i.p. to Ahr(−/−) mice, total BaP-DNA adduct 
levels were similar to those in Ahr(+/+) mice, although 
the formation of individual adduct spots determined by 
32P-postlabelling varied (Kondraganti et al. 2003). In con-
trast, in other studies, BaP-induced adduct levels in the liv-
ers of Ahr(−/−) mice were significantly higher than those 
in Ahr(+/+) mice after oral administration (Sagredo et al. 
2006, 2009). Thus, these studies provide evidence of a 
mechanism of BaP biotransformation that is Ahr independ-
ent. Whether this mechanism involves p53 function in vivo 
is currently untested and would require the creation of a 
Ahr(−/−)/Trp53(−/−) double-knockout mouse line.
We recently found that BaP-induced CYP1A1 expres-
sion in human cells can be regulated through p53 binding 
to a p53 response element (p53RE) in the regulatory region 
of CYP1A1, thereby enhancing its transcription and thus 
explaining the role of p53 function in BaP metabolism in 
vitro as described above (Wohak et al. 2014). Others have 
shown that p53 induces the activity of CYP3A4 in human 
cells via its binding to p53REs and the subsequent tran-
scriptional enhancement of CYP3A4 (Goldstein et al. 
2013). However, the induction of Cyps like Cyp1a1 via p53 
binding to a p53RE in the Cyp1a1 promoter region fails 
to explain the impact of p53 on BaP metabolism in vivo 
(present study), as Cyp1a protein levels and Cyp1a enzyme 
activity were actually higher in Trp53(−/−) mice which 
lack p53 function suggesting that the mechanism is differ-
ent in vitro and in vivo, at least in the rodent model.
It remains to be seen whether this observation is specific 
to BaP or a more general phenomenon. However, bioacti-
vation and DNA adduct formation of 3-NBA in vivo were 
not influenced by Trp53 status (present study) which is in 
concordance with previous findings that 3-NBA induces 
similar levels of DNA adducts in human TP53(+/+) and 
TP53(−/−) cell lines (Hockley et al. 2008; Simoes et al. 
2008). This observation indicates that the cellular impact 
of p53 on carcinogen metabolism depends on the agent 
studied and/or that only certain XMEs depend on p53 
function. The most efficient enzyme to activate 3-NBA to 
DNA adducts is NQO1 (Arlt et al. 2005; Stiborova et al. 
2010), and thus, NQO1 seems to be an enzyme not affected 
by p53 expression. This is in line with the fact that over-
all Nqo1 protein levels and Nqo1 enzyme activity were not 
significantly different in the Trp53(+/+), Trp53(+/–) and 
Trp53(−/−) mouse lines, after both BaP and 3-NBA treat-
ment. Future studies will be required to address this ques-
tion, thereby testing other environmental and dietary car-
cinogens both in vitro and in vivo.
In summary, we found that murine Cyp-mediated bio-
activation of BaP in vivo is influenced by p53 function, 
thereby providing new fundamental insights into PAH-
induced carcinogenesis. These results indicate that gene–
environment interactions need to be taken into account 
with regard to xenobiotic metabolism. Our results are in 
line with studies demonstrating an emerging role for p53 
in carcinogen metabolism in human cells in vitro. Whereas 
in human cells, BaP-induced CYP1A1 expression is regu-
lated through p53 binding to a p53RE in the CYP1A1 
regulatory region, thereby enhancing its transcription, the 
mechanism involved in the altered expression and activity 
of the Cyp1a1 enzyme by p53 in vivo in mice has yet to be 
identified. Future investigations will need to assess whether 
the metabolic activation of other environmental carcino-
gens depends on p53 in vivo and where the differences lie 
between murine and human p53.
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